Clearmind Medicine (NASDAQ:CMND – Get Free Report) issued its earnings results on Thursday. The company reported ($0.57) EPS for the quarter, FiscalAI reports.
Clearmind Medicine Price Performance
Clearmind Medicine stock opened at $0.97 on Friday. The company’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $4.90. The firm has a market capitalization of $986,034.00, a price-to-earnings ratio of -0.01 and a beta of 0.81. Clearmind Medicine has a fifty-two week low of $0.92 and a fifty-two week high of $524.00.
Insider Buying and Selling
In other Clearmind Medicine news, major shareholder Financial Lp Hrt sold 22,139 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.31, for a total value of $73,280.09. Following the completion of the sale, the insider directly owned 81,353 shares in the company, valued at $269,278.43. This represents a 21.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Analyst Ratings Changes
Read Our Latest Report on CMND
Clearmind Medicine Company Profile
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Recommended Stories
- Five stocks we like better than Clearmind Medicine
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
